The acquisition advances Intertek’s strategic growth in expert support services to the global pharmaceutical, medical device and drug delivery industry. BioClin will operate in Intertek’s Pharmaceutical Services Group within its analytical services division.
Andrew Swift, executive vice president of Intertek’s analytical services division, said: “Acquiring BioClin, further expands Intertek’s support globally to the pharmaceutical and related sectors for outsourced R&D and analytical services.”